<DOC>
	<DOCNO>NCT00096863</DOCNO>
	<brief_summary>Delirium associate increase risk death , prolong stay , high cost care , likely long-term brain deficit survivor . This form brain dysfunction occur intensive care unit ( ICU ) patient epidemic proportion , scope problem likely worsen upcoming year due age population increase utilization ICU . Currently , delirium go unrecognized untreated vast majority circumstance ICU unless patient present hyperactive delirium agitation . In latter circumstance , commonly use typical antipsychotic call haloperidol consider principal agent treat delirium base largely anecdotal evidence support usefulness , though placebo control trial exist . There FDA approve medication delirium . The atypical antipsychotic provide promise alternative treatment delirium due enhance beneficial effect positive ( agitate ) negative ( quiet ) symptom prove mania schizophrenia , reduce risk side effect common haloperidol extrapyramidal symptomatology , less potentially lethal heart rhythm disturbance . It imperative well-designed phase II study determine proof principle conduct . A pilot study feasibility begin assess role antipsychotic management ICU delirium .</brief_summary>
	<brief_title>The MIND Study : Modifying INcidence Delirium</brief_title>
	<detailed_description>This investigation first placebo control trial delirium prevention/treatment , ICU . As mention , clinical practice guideline medical management pain , anxiety , delirium ( major determinant patient comfort ) endorse major critical care society . These guideline form template investigation . Pain management prioritize clinician ' first concern . The assessment treatment algorithm guideline place anxiety delirium , respectively , sequential tier priority . While delirium monitoring available , recent data indicate less 5 % practice ICU healthcare professional use specific delirium monitoring instrument . Thus , outline , delirium recognize treat , serve rationale placebo-controlled investigation . Anxiety currently treat drug benzodiazepine . Such anxiety , however , may due delirium , case treatment anxiolytic benzodiazepine might exacerbate form brain dysfunction . On hand , possible treatment antipsychotic reduce duration severity delirium , result le breakthrough sedative ( due sedate effect antipsychotic ) , improve clinical outcome . Alternatively , treatment antipsychotic may alter worsen clinical outcome . The specific aim study follow : Aim 1 : To determine whether antipsychotic reduce incidence duration delirium high risk mechanically ventilated patient . Aim 2 : To determine whether antipsychotic reduce severity neuropsychological dysfunction hospital discharge high risk mechanically ventilated patient . Hypothesis 1 : Our primary hypothesis mechanically ventilated patient , duration delirium day alive free delirium - measure use Confusion Assessment Method ICU ( CAM-ICU ) - significantly improve early treatment antipsychotic ( haloperidol ziprasidone ) compare placebo . Furthermore , hypothesize delirium duration comparable two intervention group ( haloperidol ziprasidone ) . To test primary hypothesis , propose perform randomize , double-blind , placebo-controlled trial prevention/treatment delirium ICU patient use oral liquid formulation haloperidol versus ziprasidone versus placebo . This study power show 50 % improvement duration delirium ( CAM-ICU positive day ) enroll 102 patient ( 34 group ) two-year period . In addition , compare group overall incidence delirium number delirium free day ( DFDs ) - define day alive free coma delirium day 21 . Hypothesis 2 : We hypothesize score neuropsychological test battery administer time hospital discharge well patient treated antipsychotic ( either haloperidol ziprasidone ) treat placebo . Furthermore , hypothesize neuropsychological test score comparable two intervention group ( haloperidol ziprasidone ) .</detailed_description>
	<mesh_term>Delirium</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<mesh_term>Haloperidol</mesh_term>
	<mesh_term>Haloperidol decanoate</mesh_term>
	<criteria>Medical surgical ICU patient mechanical ventilation receive sedative analgesic display abnormal level consciousness ( delirium coma ) . Subjects expect short time mechanical ventilation . That , likelihood need mechanical ventilation le 24 hour . Subjects mechanical ventilation 72 hour . Subjects gastric access available ( i.e. , enteral feeding tube NG/OG tube ) anticipate available 48 hour . Subjects young 18 year old . Subjects pregnant ( pregnancy test perform woman child bear age ) breastfeeding . Inability obtain informed consent subject subject 's authorized representative . Documented history allergic reaction ziprasidone haloperidol . Subjects admit ICU drug/alcohol overdose , suicide attempt , alcohol withdrawal/delirium tremens . Subjects active seizure cerebrovascular accident within last 2 week . Subjects benzodiazepine dependent time index hospitalization ( i.e. , patient benzodiazepines outpatient whose attend judge unsafe withhold medication due risk withdrawal syndrome ) . Subjects chronic pain syndrome maintenance narcotic . Subjects history torsades de pointes , know history QT prolongation ( e.g. , congenital long QT syndrome ) , QTc baseline 500 ms absence bundle branch block , document myocardial infarction within previous 2 week , uncompensated NYHA IV heart failure ( dyspnea anginal syndrome present rest due CHF ) . [ NOTE : ICU patient incidental rise troponin absence definitive ischemic ECG change remain eligible ] Subjects neuroleptic therapy outpatient maintenance drug ( e.g. , haloperidol , mesoridazine , thorazine , chlorpromazine , trifluoperazine , droperidol , risperidone , quetiapine , olanzapine , ziprasidone ) . Subjects receive continue receive drug prolong QT interval sotalol , quinidine , Class Ia III antiarrhythmic , dofetilide ( Tikosyn arrhythmias ) , pimozide ( Tourette 's ) , gatifloxacin , moxifloxacin ( levofloxacin permissible ) , pentamidine , tacrolimus ( Prograf ) , dolasetron ( Anzemet ) . Azithromycin acceptable medication study patient , anyone slat receive ( receive ) either clarithromycin erythromycin switch azithromycin primary team enrol study follow day . Patients receive clindamycin clotrimazole exclude study . Subjects history neuroleptic malignant syndrome . Subjects potassium level 3.0 mg/dl magnesium level 1.8 mg/dl . NOTE : If patient receive replacement K+ Mg+ , he/she would eligible unless reason suspect electrolyte abnormality refractory . Subjects moderate/severe dementia ( e.g. , Alzheimer 's type , vascular origin , HIVrelated ) document medical history modify Blessed dementia rating scale ( mBDRS ) 4 Informant Questionnaire Cognitive Dysfunction Elderly ( IQCODE ) 3.6 . Subjects suspect anoxic brain injury document cerebral edema time screen . Subjects moribund expect survive 24 hour time study enrollment , `` Do Not Resuscitate '' order , whose family medical team commit aggressive support ( e.g. , go use vasopressor mechanical ventilation likely withdrawal support within 24 hour ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Delirium</keyword>
	<keyword>Cognition Disorders</keyword>
	<keyword>Antipsychotics</keyword>
	<keyword>Mechanical Ventilation</keyword>
	<keyword>Critical Illness</keyword>
</DOC>